## Candida Species: Epidemiology, Resistance, and Clinical Associations ### Overview of Non-albicans Candida Species **Key Point:** Non-albicans Candida species are increasingly prevalent in healthcare settings and often display antifungal resistance patterns that differ from C. albicans, necessitating species-level identification and susceptibility testing. ### Comparison of Major Candida Species | Species | Key Features | Antifungal Resistance | Clinical Association | |---------|--------------|----------------------|----------------------| | **C. auris** | Emerging pathogen, high mortality (30–60%), multidrug-resistant | Fluconazole-resistant; variable echinocandin susceptibility | Nosocomial outbreaks, ICU, immunocompromised | | **C. glabrata** | Intrinsic azole resistance | Resistant to azoles; susceptible to echinocandins, amphotericin B | Bloodstream infections, UTIs, older patients | | **C. tropicalis** | Invasive potential, biofilm former | Variable azole resistance | Invasive infections, but LESS common than C. albicans in blood cultures | | **C. parapsilosis** | Biofilm producer, catheter-associated | Reduced echinocandin susceptibility | Catheter-related bloodstream infections, medical device infections | ### Why Option 3 is Incorrect **High-Yield:** Candida tropicalis is **NOT** more commonly isolated from blood cultures than C. albicans. Despite being invasive and capable of causing severe infections, C. albicans remains the most frequent Candida species in bloodstream infections globally. C. tropicalis ranks 3rd or 4th in frequency, after C. glabrata and C. auris in many developed healthcare settings. **Clinical Pearl:** While C. tropicalis has high invasive potential and is associated with disseminated disease in immunocompromised patients, epidemiological data consistently show C. albicans as the predominant species in candidemia, followed by C. glabrata in many regions. ### Why the Other Options Are Correct - **Option 1 (C. auris):** Confirmed — emerging multidrug-resistant pathogen with high mortality; intrinsically resistant to fluconazole and often to other azoles. - **Option 2 (C. glabrata):** Confirmed — intrinsically resistant to azoles due to altered lanosterol 14α-demethylase; echinocandins are first-line therapy. - **Option 4 (C. parapsilosis):** Confirmed — strongly associated with catheter-related infections and biofilm formation on prosthetic materials.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.